Glutamate activates the MAPK pathway by inhibiting LPAR1 expression and promotes anlotinib resistance in thyroid cancer
Our study revealed that glutamate promotes the progression of malignant biological behavior in TC cell lines and TC-anlotinib-resistant cell lines. Additionally, glutamate may activate the MAPK pathway by inhibiting the expression of LPAR1, thereby promoting resistance to anlotinib in TC.
Authors
- Lei Cha
- Chang Diao (ORCID: https://orcid.org/0000-0003-0756-2471)
- Ruochuan Cheng (ORCID: https://orcid.org/0000-0002-9527-6928)
- Yanjun Su (ORCID: https://orcid.org/0009-0002-0725-1243)
- Ying Peng
- Bin Liu (ORCID: https://orcid.org/0009-0007-7565-5844)
Institutions
- Kunming Medical University (CN)
- First Affiliated Hospital of Kunming Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1007/s12672-025-02853-0
- Citations
- 2
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.87
Funders
- National Natural Science Foundation of China